Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multi-Center Phase 2 Open-Label Study to Evaluate Safety and Efficacy in Subjects With Melanoma Metastatic to the Brain Treated With Nivolumab in Combination With Ipilimumab Followed by Nivolumab Monotherapy

Trial Profile

A Multi-Center Phase 2 Open-Label Study to Evaluate Safety and Efficacy in Subjects With Melanoma Metastatic to the Brain Treated With Nivolumab in Combination With Ipilimumab Followed by Nivolumab Monotherapy

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 04 Jun 2019

At a glance

  • Drugs Ipilimumab (Primary) ; Nivolumab (Primary)
  • Indications Brain metastases; Malignant melanoma
  • Focus Therapeutic Use
  • Acronyms CheckMate204
  • Sponsors Bristol-Myers Squibb
  • Most Recent Events

    • 04 Jun 2019 Results (data cut off: May 1, 2018) assessing efficacy and safety of the combination of nivolumab plus ipilimumab in patients with melanoma brain metastases presented at the 55th Annual Meeting of the American Society of Clinical Oncology
    • 16 May 2019 According to a Bristol-Myers Squibb Media Release, data from this trial will be presented at the upcoming American Society of Clinical Oncology (ASCO) Annual Meeting 2019 in Chicago, May 31-June 4, and the 24th Annual Congress of the European Hematology Association (EHA) in Amsterdam, June 13-16.
    • 04 Dec 2018 Results assessing outcome of 34 cHL patients who received an Allo-SCT after treatment with PD-1 inhibitors in patients enrolled in CA209-205, CA209-254 and MK3475087 trials presented at the 60th Annual Meeting and Exposition of the American Society of Hematology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top